Exelixis | EXEL - Interest Income


Exelixis reported $14.32M in Interest Income for its fiscal quarter ending in September of 2026.





Interest Income Change Date
Acadia Pharmaceuticals USD 7.99M 65K Jun/2026
Agios Pharmaceuticals USD 9.73M 1.06M Jun/2026
AstraZeneca USD 80M 7M Jun/2026
Bayer EUR 169M 39M Dec/2025
BioMarin Pharmaceutical USD 10.48M 12.08M Jun/2026
Cytokinetics USD 13.94M 2.92M Jun/2026
Eisai JPY 3.11B 783M Mar/2024
Eli Lilly USD 65M 25M Sep/2025
Exelixis USD 14.32M 105K Sep/2026
Genmab DKK 14M 11M Mar/2026
Glaxosmithkline GBP 29M 7M Sep/2026
Incyte USD 38.12M 4.43M Jun/2026
Ionis Pharmaceuticals USD -0.66 0.29 Dec/2024
MacroGenics USD 1.37M 186K Jun/2026
Merck USD 35M 0 Jun/2026
Moderna USD 67M 5M Jun/2026
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Pfizer USD 0.56 0.6 Sep/2026
Puma Biotechnology USD 0.41 0.5 Sep/2024
Sanofi EUR 77M 17M Jun/2026
Takeda JPY 14.57B 10.04B Sep/2026
Ultragenyx Pharmaceutical USD 5M 1000K Jun/2026
Xencor USD 4.8M 659K Jun/2026